Summary of Recent Deal Activities
- PDF / 103,806 Bytes
- 8 Pages / 613.72 x 793.04 pts Page_size
- 50 Downloads / 183 Views
Int J Pharm Med 2004; 18 (2): 97-104 1364-9027/04/0002-0097/$31.00/0 © 2004 Adis Data Information BV. All rights reserved.
Summary of Recent Deal Activities Drug Discovery Technologies
Companies Angiotech Pharmaceuticals, Inc., Poly-Med, Inc.
Astex Technology
AstraZeneca, plc, NeoGenesis Pharmaceuticals, Inc.
AstraZeneca, Astex Technology
AstraZeneca, PerkinElmer, Inc.
Type of deal Details Licensing agreement Angiotech Pharmaceuticals, Inc. has licensed a portfolio of biomaterial, drug-delivery and medical device technologies from Poly-Med, Inc. This agreement will expand Angiotech’s relationship with Poly-Med, which it initially formalised in a June 2001 licensing agreement. The collaboration grants Angiotech exclusive rights to several of Poly-Med’s key technologies, including a portfolio of absorbable and biodegradable polymers and drug-delivery technologies that are potentially useful in several areas, including tissue repair, orthopaedic surgery and vascular surgery. The two companies will also collaborate on research to develop products derived from the licensed technologies, and explore the application of these technologies to drug-loaded medical device and biomaterial research efforts already underway at Angiotech. R&D agreement Astex Technology, The Wellcome Trust, the Institute of Cancer Research and Cancer Research Technology are co-operating in an exclusive collaboration relating to the discovery of drugs against the cancer target BRAF. BRAF was first identified as a key target implicated in a variety of cancers in 2002 when scientists discovered that the gene is involved in up to 70% of certain cancer types including malignant melanoma. The Institute of Cancer Research, The Wellcome Trust and Cancer Research Technology began a drug-discovery collaboration in 2003 to identify BRAF inhibitors, and have been joined by Astex who will contribute expertise in fragment-based drug discovery to the collaboration. Under the terms of the agreement, the partners have established a joint research team to identify and develop drug candidates for major indications in oncology. This programme will combine the expertise of the partners in fragment-based drug discovery, cancer biology and the preclinical and clinical development of cancer drugs. R&D agreement NeoGenesis Pharmaceuticals, Inc. has signed an R&D collaboration agreement with AstraZeneca, plc. This collaboration will focus on the discovery of small molecules aimed at certain human diseases, including oncological, infection, cardiovascular, CNS and inflammatory diseases. Under the terms of this agreement, NeoGenesis will use its drug-discovery technologies, including its proprietary Automated Ligand Identification System (ALIS) platform, NeoMorph compound libraries and lead optimisation technologies to discover drug candidates against selected targets. Under the terms of the agreement, NeoGenesis will receive research funding, payment for achieving research and development milestones, and royalties based on the successful commercialisation of drug cand
Data Loading...
